Claims

1. The use of a compound that is seladelpar or a salt thereof in the manufacture of a medicament for treating an intrahepatic cholestatic disease at a dose of 5 mg/day or 10 mg/day, when the dose is calculated as seladelpar.

2. The use of claim 1 where the compound is seladelpar L-lysine dihydrate.

3. The use of claim 1 or 2 where the compound is to be administered orally.

4. The use of any one of claims 1 to 3 where the dose of the compound is 5 mg/day.

5. The use of any one of claims 1 to 3 where the dose of the compound is 10 mg/day.

6. The use of any one of claims 1 to 5 where the compound is to be administered once/day.

7. The use of any one of claims 1 to 6 where the intrahepatic cholestatic disease is primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

8. The use of claim 7 where the intrahepatic cholestatic disease is primary biliary cholangitis.

9. The use of claim 7 where the intrahepatic cholestatic disease is primary sclerosing cholangitis.

10. The use of claim 7 where the intrahepatic cholestatic disease is progressive familial intrahepatic cholestasis.

11. The use of claim 7 where the intrahepatic cholestatic disease is Alagille syndrome.

12. An oral pharmaceutical composition comprising a compound that is seladelpar or a salt thereof, where the amount of the compound is equivalent to 5 mg or 10 mg of seladelpar.

13. The oral pharmaceutical composition of claim 12 where the amount of the compound is equivalent to 5 mg of seladelpar.

14. The oral pharmaceutical composition of claim 12 where the amount of the compound is equivalent to 5 mg of seladelpar.

15. The oral pharmaceutical composition of any one of claims 12 to 14 that is a tablet or a capsule.